Generic Copaxone is coming

Share this article:

Teva's push to keep generic Copaxone off the market its over. Bloomberg reports the company lost its suit to keep generics at bay, just 10 days before the expiration of the branded MS drug's patent.

Teva wanted more testing of generic versions of the drug, but a federal judge said forget it.

The company has prepped investors for the possibility that its major drug could get competition this year, and even went so far as to provide two 2014 forecasts: one in which Copaxone had the market to itself, and other in which it did not.

Despite generics concern, the company has been able to convert Copaxone users to a newer, patent-protected formulation.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.